Rubicon Research

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE506V01022
  • NSEID: RUBICON
  • BSEID: 544578
INR
1,327.00
-16.3 (-1.21%)
BSENSE

Jun 16, 11:20 AM

BSE+NSE Vol: 4.67 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

4.67 lacs (17.72%) Volume

Shareholding (Mar 2026)

FII

7.54%

Held by 28 FIIs

DII

10.02%

Held by 11 DIIs

Promoter

59.86%

Why is Rubicon Research Ltd falling/rising?

16-Jun-2026

As of 15-Jun, Rubicon Research Ltd's stock price is rising, currently at 1,343.30, reflecting a 3.78% increase. The stock has shown significant growth year-to-date at 98.19%, driven by strong financial results and positive market performance.

As of 15-Jun, Rubicon Research Ltd's stock price is rising, currently at 1,343.30, reflecting an increase of 48.95 (3.78%). This upward movement can be attributed to several factors. Over the past week, the stock has gained 13.95%, significantly outperforming the Sensex, which only rose by 3.73%. In the last month, the stock has surged by 39.56%, while the Sensex has seen a modest increase of 1.36%. Year-to-date, Rubicon Research has shown remarkable growth of 98.19%, contrasting sharply with the Sensex's decline of 10.51%.<BR><BR>Today's performance further highlights the stock's strength, as it opened with a gain of 2.42% and reached an intraday high of Rs 1,363.2, marking a 5.32% increase. The stock has been on a consecutive gain streak for four days, accumulating a total return of 16.1% during this period. Additionally, it is trading above all key moving averages, indicating a strong bullish trend.<BR><BR>Despite a slight decline in investor participation, with delivery volume falling by 16.59% against the five-day average, the stock remains liquid enough for trading. The positive financial results, including an 88.33% growth in net profit and strong operating metrics, contribute to the stock's appeal. Overall, the combination of strong recent performance, positive financial indicators, and a favorable market position supports the rise in Rubicon Research Ltd's stock price.

View full answer

What does Rubicon Research do?

11-Jun-2026

Rubicon Research Ltd is a small-cap company in the Pharmaceuticals & Biotechnology sector, reporting net sales of 514 Cr and a net profit of 77 Cr for the quarter ending March 2026. It has a market cap of INR 19,408 Cr, a P/E ratio of 80.00, and a return on equity of 19.14%.

Overview: <BR>Rubicon Research Ltd is a company operating in the Pharmaceuticals & Biotechnology industry within the Small Cap market-cap bracket.<BR><BR>History: <BR>Rubicon Research Limited was incorporated on May 6, 1999, originally as Rubicon Consultants Private Limited. The company later changed its name to Rubicon Research Private Limited, receiving a fresh Certificate of Incorporation on September 2, 2002. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 514 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 77 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 19,408 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 80.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.03 <BR>Return on Equity: 19.14% <BR>Price to Book: 14.97<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

View full answer

How big is Rubicon Research?

11-Jun-2026

As of 10th June, Rubicon Research Ltd has a market capitalization of 19,408.00 Cr, with recent Net Sales of 1,753.96 Cr and a Net Profit of 246.74 Cr.

As of 10th June, Rubicon Research Ltd has a market capitalization of 19,408.00 Cr, categorizing it as a Small Cap company.<BR><BR>For the latest four quarters, Rubicon Research reported Net Sales of 1,753.96 Cr and a Net Profit of 246.74 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 540.98 Cr and Total Assets of 1,449.66 Cr.

View full answer

Who are the peers of the Rubicon Research?

11-Jun-2026

Rubicon Research's peers include Neuland Labs, Piramal Pharma, Astrazeneca Pharma, Pfizer, ERIS Lifescience, Granules India, Caplin Point Lab, Cohance Life, OneSource Specialty, and Natco Pharma, with varying management risk and growth ratings. Granules India leads in 1-year returns at 44.87%, while Piramal Pharma has the lowest at -20.05%.

Peers: The peers of Rubicon Research are Neuland Labs., Piramal Pharma, Astrazeneca Phar, Pfizer, ERIS Lifescience, OneSource Speci., Granules India, Caplin Point Lab, Cohance Life, and Natco Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Astrazeneca Phar, while Good management risk is found at Neuland Labs., Pfizer, ERIS Lifescience, Granules India, Caplin Point Lab, and Natco Pharma, and Average management risk is noted at Cohance Life, while Below Average management risk is present at OneSource Speci. and Piramal Pharma. Growth is Excellent at OneSource Speci., Good at Neuland Labs., Piramal Pharma, and Granules India, while Below Average growth is seen at Astrazeneca Phar, Pfizer, ERIS Lifescience, Caplin Point Lab, Cohance Life, and Natco Pharma. For Capital Structure, Excellent ratings are given to Neuland Labs., Astrazeneca Phar, Pfizer, Granules India, Caplin Point Lab, and Cohance Life, while Good is noted for ERIS Lifescience, and Below Average is seen at Piramal Pharma and OneSource Speci.<BR><BR>Return Snapshot: Granules India has the highest 1-year return at 44.87%, while Piramal Pharma has the lowest at -20.05%, with Rubicon Research's 1-year return being N/A. Additionally, peers with negative six-month returns include ERIS Lifescience, OneSource Speci., Cohance Life, and Piramal Pharma.

View full answer

Should I buy, sell or hold Rubicon Research Ltd?

03-Jun-2026

When is the next results date for Rubicon Research Ltd?

28-Jan-2026

The next results date for Rubicon Research Ltd is 03 February 2026.

The next results date for Rubicon Research Ltd is scheduled for 03 February 2026.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%

  • Healthy long term growth as Net Sales has grown by an annual rate of 0% and Operating profit at 0%
  • Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.78 times
2

With a growth in Net Profit of 88.33%, the company declared Outstanding results in Mar 26

3

Majority shareholders : Promoters

 
stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 21,862 Cr (Small Cap)

stock-summary
P/E

91.00

stock-summary
Industry P/E

34

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.03

stock-summary
Return on Equity

19.14%

stock-summary
Price to Book

17.36

Revenue and Profits:
Net Sales:
514 Cr
(Quarterly Results - Mar 2026)
Net Profit:
77 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
76.99%
0%
76.99%
6 Months
107.15%
0%
107.15%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Rubicon Research for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
0
EBIT to Interest (avg)
6.10
Debt to EBITDA (avg)
1.50
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.16
Tax Ratio
23.02%
Dividend Payout Ratio
0.23%
Pledged Shares
0
Institutional Holding
17.55%
ROCE (avg)
25.58%
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
91
Industry P/E
34
Price to Book Value
17.36
EV to EBIT
62.93
EV to EBITDA
55.81
EV to Capital Employed
17.82
EV to Sales
12.74
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
28.31%
ROE (Latest)
19.14%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
RSI
Bearish
Bollinger Bands
Bullish
KST
Dow Theory
Mildly Bearish
Bullish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 12 Schemes (7.14%)

FIIs

Held by 28 FIIs (7.54%)

Promoter with highest holding

General Atlantic Singapore Rr Pte Ltd (35.89%)

Highest Public shareholder

Shivanand Shankar Mankekar Huf (13.54%)

Individual Investors Holdings

2.82%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 29.22% vs -10.33% in Dec 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 88.33% vs -18.84% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "389.88",
          "val2": "301.71",
          "chgp": "29.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "106.17",
          "val2": "62.24",
          "chgp": "70.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "5.40",
          "val2": "7.51",
          "chgp": "-28.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "70.02",
          "val2": "37.18",
          "chgp": "88.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "27.23%",
          "val2": "20.63%",
          "chgp": "6.60%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "614.49",
          "val2": "528.16",
          "chgp": "16.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "142.24",
          "val2": "144.68",
          "chgp": "-1.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "18.06",
          "val2": "16.26",
          "chgp": "11.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "80.96",
          "val2": "89.04",
          "chgp": "-9.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "23.15%",
          "val2": "27.39%",
          "chgp": "-4.24%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "916.20",
          "val2": "773.03",
          "chgp": "18.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "204.48",
          "val2": "208.58",
          "chgp": "-1.97%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "25.57",
          "val2": "23.51",
          "chgp": "8.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "118.14",
          "val2": "127.27",
          "chgp": "-7.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "22.32%",
          "val2": "26.98%",
          "chgp": "-4.66%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 36.57% vs 50.40% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 83.64% vs 47.63% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,753.96",
          "val2": "1,284.27",
          "chgp": "36.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "400.24",
          "val2": "264.26",
          "chgp": "51.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "42.17",
          "val2": "36.78",
          "chgp": "14.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "246.74",
          "val2": "134.36",
          "chgp": "83.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "22.82%",
          "val2": "20.58%",
          "chgp": "2.24%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Mar'26 - QoQstock-summary

Mar'26
Dec'25
Change(%)
Net Sales
389.88
301.71
29.22%
Operating Profit (PBDIT) excl Other Income
106.17
62.24
70.58%
Interest
5.40
7.51
-28.10%
Exceptional Items
0.00
0.00
Standalone Net Profit
70.02
37.18
88.33%
Operating Profit Margin (Excl OI)
27.23%
20.63%
6.60%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2026 is 29.22% vs -10.33% in Dec 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is 88.33% vs -18.84% in Dec 2025

Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
614.49
528.16
16.35%
Operating Profit (PBDIT) excl Other Income
142.24
144.68
-1.69%
Interest
18.06
16.26
11.07%
Exceptional Items
0.00
0.00
Standalone Net Profit
80.96
89.04
-9.07%
Operating Profit Margin (Excl OI)
23.15%
27.39%
-4.24%
Values in Rs Cr.
Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

Nine Monthly Results Snapshot (Standalone) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
916.20
773.03
18.52%
Operating Profit (PBDIT) excl Other Income
204.48
208.58
-1.97%
Interest
25.57
23.51
8.76%
Exceptional Items
0.00
0.00
Standalone Net Profit
118.14
127.27
-7.17%
Operating Profit Margin (Excl OI)
22.32%
26.98%
-4.66%
Values in Rs Cr.
Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

Annual Results Snapshot (Consolidated) - Mar'26stock-summary

Mar'26
Mar'25
Change(%)
Net Sales
1,753.96
1,284.27
36.57%
Operating Profit (PBDIT) excl Other Income
400.24
264.26
51.46%
Interest
42.17
36.78
14.65%
Exceptional Items
0.00
0.00
Consolidate Net Profit
246.74
134.36
83.64%
Operating Profit Margin (Excl OI)
22.82%
20.58%
2.24%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2026 is 36.57% vs 50.40% in Mar 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2026 is 83.64% vs 47.63% in Mar 2025

stock-summaryCompany CV
About Rubicon Research Ltd stock-summary
stock-summary
Rubicon Research Ltd
Small Cap
Pharmaceuticals & Biotechnology
Rubicon Research Limited was incorporated on May 6, 1999, as a Private Company as `Rubicon Consultants Private Limited', with the RoC. Subsequently, the Company's name was changed from `Rubicon Consultants Private Limited' to `Rubicon Research Private Limited' to which a fresh Certificate of Incorporation was issued by the RoC dated September 2, 2002.
Company Coordinates stock-summary
Icon
No Company Details Available